Shares of AbbVie Inc. ABBV slumped 0.26% to $192.94 Wednesday, on what proved to be an all-around rough trading session for ...

The stock's fall snapped a two-day winning streak.

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

On CNBC's “Halftime Report Final Trades,” Stephen L. Weiss of Short Hills Capital Partners recommended buying TransDigm Group ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $196.42 which represents a slight increase of $3.02 or 1.56% from the prior close of $193.4. The stock opened at $194.97 and touched a ...

The next frame shows the Ubrelvy logo in the backstage hallway along with a blue lit path. Frames six to seven then show Serena Williams walking down the blue lit path, no longer exhibiting migraine ...

Pharmaceutical giant AbbVie has sued cancer treatment maker BeiGene in Chicago federal court, accusing it of stealing trade ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $192.86 which represents a decrease of $-4.15 or -2.11% from the prior close of $197.01. The stock opened at $196.96 and touched a low of $192.